Abstract:Abstract Abstract 4788 ObjectiveF Honokiol(HNK),an active component purified from the bark of Magnolia officianlis, consists of biphenyl skeleton with phenolic and allylic functionalities. It has showed a variety of pharmacological effects. Most attraction to us among them is antitumor effect including cytotoxicity, inducing cell differentiation and apoptosis, anti-angiogenisis, inhibiting activity of enzyme and synthesis of DNA and RNA. However, the extrem water insolubility hampers it's delivering to the tumor at an effective concentration. Liposomes have previously been used as carriers for delivery of a variety of drugs and they can improve water solubility, biodistribution and metabolism of those drugs. In the present study, we encapsulated honokiol in the non-aqueous interior of the polyethyleng glycolliposome. The antitumor efficacy and its mechanism of liposomal honokiol was investigated in vivo. MethodsF The honokiol encapsulated by liposomes was preparated in our laboratory. The tumor model was established in C57BL/6 mice by injection of EL-4 lymphoma cells. When tumor became visible about seven days after injection, the mice were randomized into six groups (10 mice each group) and treated with different doses of liposomal honokiol(LH), empty liposome, Normal Saline(NS) and Adriamycin(ADM), respectively. Tumor volume and survival time were observed. Antiangiogenesis, antilymphangiogenesis and tumor proliferative index of the tumor tissues were determined by CD31, D2-40 and Ki-67 immunohistochemistry staining, meanwhile the tumor apoptosis index was measured by TUNEL method. ResultsF In mouse lymphoma model liposomal honokiol obviously inhibited the growth of tumor in dose-dependent manner. After treatment, the tumor growth inhibition rate in 10mg/kg LH group was 49.54%,meanwhile the one in 20mg/kg LH group was 66.47%.The tumor volumes in 10mg/kg LHA20mg/kg LH and 5mg/kg ADM groups were significantly different compared with NS and LIP groups(P<0.05).No difference were observed in the tumor volumes between the 5mg/kg LHANS and LIP groups(P>0.05).There is significant difference in tumor volumes between 20mg/kg LH and 5mg/kg LH groups(P<0.05). In terms of survival investigation, the median survival time in NS and LIP groups were 30 days. No mice in these two groups were alive after the completion of study. Meanwhile the median survival time in 20mg/kg LH group was 36 days, with the survival time of 33% of mice in this group was longer than 60 days. The survival times in 10mg/kg LHA20mg/kg LH and 5mg/kg ADM groups were significantly different compared with NS and LIP groups(P<0.05). No intolerant sideeffects in liposomal honokiol-treated groups were observed in the present study. Compared with NS group, the MVD, LMVD, apoptosis index and proliferative index in 20mg/kg LH group were significantly different(P<0.05). ConclusionsF In mouse lymphoma model liposomal honokiol markedly inhibited the growth of tumor, prolonged the survival time in dose-dependent manner. Liposomal honokiol exerted its inhibitory effect by blocking angiogenesis and lymphangiogenesis, inducing tumor cell apoptosis and suppressing tumor proliferation. These findings may be of importance for further exploration of the potential application of liposomal honokiol in the treatment of lymphoma. Disclosures: No relevant conflicts of interest to declare.

Liposomal Honokiol, a Potent Anti-Angiogenesis Agent, in Combination with Radiotherapy Produces a Synergistic Antitumor Efficacy Without Increasing Toxicity.

Inhibitory Effects of Liposomal Honokiol on the Lymphoma.

Improved Therapeutic Effectiveness by Combining Liposomal Honokiol with Cisplatin in Lung Cancer Model

Anti-tumor efficacies of liposomal honokiol combined with cisplatin in lewis lung cancer and human a 549 lung cancer models: P3-027

Synergistic Antitumor Effects of Liposomal Honokiol Combined with Adriamycin in Breast Cancer Models.

Honokiol Induces Apoptosis and Autophagy Via the ROS/ERK1/2 Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo.

Liposomal Honokiol Inhibits Non-Small Cell Lung Cancer Progression and Enhances PD-1 Blockade Via Suppressing M2 Macrophages Polarization

Honokiol Augments the Anti-Cancer Effects of Oxaliplatin in Colon Cancer Cells

Liposomal Honokiol Inhibits Vegf-D-Induced Lymphangiogenesis and Metastasis in Xenograft Tumor Model

PUB045 Anti-Tumor Effect of Honokiol in Lung Squamous Cell Carcinoma

Liposomal Honokiol Induced Lysosomal Degradation of Hsp90 Client Proteins and Protective Autophagy in Both Gefitinib-Sensitive and Gefitinib-Resistant Nsclc Cells

Formylated Honokiol Analogs Showed Antitumor Activity Against Lung Carcinoma

Liposomal Honokiol, a Promising Agent for Treatment of Cisplatin-Resistant Human Ovarian Cancer.

A Novel Honokiol Liposome: Formulation, Pharmacokinetics, and Antitumor Studies.

Honokiol induces apoptosis of lung squamous cell carcinoma by targeting FGF2-FGFR1 autocrine loop.

Improved Therapeutic Efficacy Against Murine Carcinoma By Combining Honokiol With Gene Therapy Of Pnas-4, A Novel Pro-Apoptotic Gene

Use of honokiol in lung cancer therapy: a mini review of its pharmacological mechanism

Enhancement of Therapeutic Effectiveness by Combining Liposomal Honokiol with Cisplatin in Ovarian Carcinoma

Honokiol inhibits interleukin-induced angiogenesis in the NSCLC microenvironment through the NF-κB signaling pathway

Honokiol: a Promising Small Molecular Weight Natural Agent for the Growth Inhibition of Oral Squamous Cell Carcinoma Cells.

Honokiol Induces Ferroptosis In Colon Cancer Cells By Regulating Gpx4 Activity